Public Policy Committee

BioNJ’s Public Policy Committee serves as an important sounding board for BioNJ’s public policy efforts. The committee is comprised of executive and policy leadership in New Jersey’s life sciences innovation sector, from CEOs to government relations personnel and others. The committee meets regularly to provide BioNJ with feedback on policy machinations in Trenton and beyond; while participating in monthly update calls with BioNJ staff. Committee members frequently hear from guest speakers, including legislators, administrative and regulatory leaders, and others in the life sciences community at committee meetings, events and receptions. Contact BioNJ’s Senior Vice President, Government Affairs & Policy, Dr. Ian McLaughlin, to learn more about BioNJ’s federal and state policy efforts at IMclaughlin@BioNJ.org.

Members:

AbbVie – Joseph Oros, Director, State Government Affairs
Acadia Pharmaceuticals – Ben Chandhok, Director, State Government Affairs & Policy
Acadia Pharmaceuticals – Mike Mattoon, Vice President, Government Affairs & Policy
Adiso Therapeutics – Scott Megaffin, CEO
Ascendis Pharma, Kathy Kulkarni, Head, US Public Affairs
BeOne Medicines – Jen Branstetter, Director, U.S. Patient Advocacy & Public Affairs
BeOne Medicines – Rebecca (Becca) Davison, Director, U.S. Public Policy
BeOne Medicines – Kristin Dolinski, Director, US Regulatory Policy and Intelligence
BeOne Medicines – John Halliwell, Senior Director, Head of U.S. Government Affairs & Policy
BioAegis Therapeutics – Susan Levinson, CEO
BioMarin – Laura Srebnik, Associate Director, State Government Affairs – East
Biotechnology Innovation Organization (BIO) – Steve Burm, Director, State Government Affairs, NE
Bristol Myers Squibb – Grant Cale, Senior Director, Strategic Alliance & Issue Advocacy
Bristol Myers Squibb Company – Ethan Hasbrouck, MPA, State Government Affairs
CorMedix – Christopher Bowlin, Executive Director, Head of Public Policy & Government Affairs
Eli Lilly & Company – Timothy Lyden, Director, State Government and Business Affairs
Faegre Drinker Biddle & Reath LLP – Maureen Hardwick, Partner
Ferring Pharmaceuticals – Tegan Gelfand, Director, Government Affairs, Federal & Head of Public Policy
Ferring Pharmaceuticals – Francis Orlando, Regional Director, State Government Affairs (Northeast)
Genmab – Daniel Amburn, Regional Director, State Gov’t Affairs (US East)
Genmab – Christine Zettlemoyer, Head of Global Compliance
Gilead Sciences – Justin Rush, Director, U.S. Strategy & Policy, Government Affairs
GSK – Mary Bartlett, Director of State Government Affairs
GSK – Chris Bryce, Director, State Government Affairs, US Government Affairs and Public Policy
IBM –Tina Naser, Partner, Healthcare Life Sciences Industry
Ipsen Biopharmaceuticals – John E. Valenti, Head, State Government Affairs and State Policy
Jazz Pharmaceuticals – Daniela Sharfstein, Director, State Government Affairs
J&J – Chris Guiton, JD, Sr. Director, US State Government Affairs
J&J – Adam Taliaferro, Director, State and Community Engagement, US State Affairs
Kyowa Kirin – Ted Buckley, Vice President Government Affairs
Kyowa Kirin – Liz Parlett Butcher, MPA, Associate Director, Patient Advocacy and Policy, Rare Disease
Kyowa Kirin – Stephanie Kelly, Global Head Regulatory Intelligence and Policy
Kyowa Kirin – John Spera, Senior Director, Market Access Strategy, Rare Disease
Lexicon Pharmaceuticals – Alina Cocuzza, Head, External Affairs
Merck & Co. – Domenick Argento, Associate Director, Account Management, Government Affairs & Policy
Novartis Pharmaceuticals – Becca Durr, Director, Federal Government Affairs
Novartis Pharmaceuticals – Brianna Earle, Associate Director, State Government Affairs
Novartis Pharmaceuticals – John Hohenwarter, Associate Director, State Government Affairs
Novo Nordisk – Amanda Turner, Lead State Government Affairs
Otsuka America Pharmaceutical – Joee Lindbeck, Associate Director, State Government Affairs
Pfizer – Anna Maria Maritato, Senior Director, State Government Relations
PsychoGenics –  Emer Leahy, Ph.D., MBA, President and CEO
PTC Therapeutics – Theodore Piper, Associate Director, State Government Affairs
Sanofi – George Coutros, Director, State Government Affairs
Serotonix – John Maki, CEO
Tactical Therapeutics – Rashida Karmali, JD, Ph.D., MBA, CLP, CEO & President
Taiho Oncology – Ryan Garofalo, Associate Director, Professional Association Engagement
Teva Pharmaceuticals – Sarah Kan, Sr. Director, State Government Affairs
Vertex Pharmaceuticals – Martha Auster, Regional Director, Government Affairs
Vertex Pharmaceuticals – John Slotman, Director, State Government Affairs
Wilson Sonsini – Squire Servance, Senior Counsel